424 related articles for article (PubMed ID: 30939962)
21. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
22. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
23. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Agrawal AK; Feusner JH
Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
[No Abstract] [Full Text] [Related]
24. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
25. Rasburicase for the treatment of tumor lysis in hematological malignancies.
Malaguarnera G; Giordano M; Malaguarnera M
Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
27. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
28. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
29. Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.
Alessa MA; Craig AK; Cunningham JM
Am J Case Rep; 2015 Sep; 16():590-3. PubMed ID: 26334783
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
31. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC; Pui CH
Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
[TBL] [Abstract][Full Text] [Related]
32. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
[TBL] [Abstract][Full Text] [Related]
33. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
34. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Abousaud MI; Rush MC; Rockey M
J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
36. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
37. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
38. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
[TBL] [Abstract][Full Text] [Related]
39. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Holdsworth MT; Nguyen P
Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
